Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin

Na Man, Xiao Jian Sun, Yurong Tan, Marta García-Cao, Fan Liu, Guoyan Cheng, Megan Hatlen, Haiming Xu, Ronit Shah, Nolan Chastain, Na Liu, Gang Huang, Yuan Zhou, Mengyao Sheng, Junhong Song, Feng-Chun Yang, Robert Benezra, Stephen D Nimer, Lan Wang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Inhibitor of DNA binding 1 (Id1) functions as an E protein inhibitor, and overexpression of Id1 is seen in acute myeloid leukemia (AML) patients. To define the effects of Id1 on leukemogenesis, we expressed MLL-AF9 in fetal liver (FL) cells or bone marrow (BM) cells isolated from wild-type, Id1-/-, p21-/-, or Id1-/- p21-/- mice, and transplanted them into syngeneic recipient mice. We found that although mice receiving MLL-AF9 - transduced FL or BM cells develop AML, loss of Id1 significantly prolonged the median survival of mice receiving FL cells but accelerated leukemogenesis in recipients of BM cells. Deletion of Cdkn1a (p21), an Id1 target gene, can rescue the effect of Id1 loss in both models, suggesting that Cdkn1a is a critical target of Id1 in leukemogenesis. It has been suggested that the FL transplant model mimics human fetal-origin (infant) MLL fusion protein (FP)-driven leukemia, whereas the BM transplantation model resembles postnatal MLL leukemia; in fact, the analysis of clinical samples from patients with MLL-FP+ leukemia showed that Id1 expression is elevated in the former and reduced in the latter type of MLL-FP+ AML. Our findings suggest that Id1 could be a potential therapeutic target for infant MLL-AF9-driven leukemia.

Original languageEnglish (US)
Pages (from-to)2322-2326
Number of pages5
JournalBlood
Volume127
Issue number19
DOIs
StatePublished - 2016

Fingerprint

Leukemia
DNA
Liver
Bone
Bone Marrow Cells
Fusion reactions
Acute Myeloid Leukemia
Core Binding Factor alpha Subunits
Transplants
Proteins
Bone Marrow Transplantation
Genes
Cells

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Man, N., Sun, X. J., Tan, Y., García-Cao, M., Liu, F., Cheng, G., ... Wang, L. (2016). Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin. Blood, 127(19), 2322-2326. https://doi.org/10.1182/blood-2015-11-677708

Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin. / Man, Na; Sun, Xiao Jian; Tan, Yurong; García-Cao, Marta; Liu, Fan; Cheng, Guoyan; Hatlen, Megan; Xu, Haiming; Shah, Ronit; Chastain, Nolan; Liu, Na; Huang, Gang; Zhou, Yuan; Sheng, Mengyao; Song, Junhong; Yang, Feng-Chun; Benezra, Robert; Nimer, Stephen D; Wang, Lan.

In: Blood, Vol. 127, No. 19, 2016, p. 2322-2326.

Research output: Contribution to journalArticle

Man, N, Sun, XJ, Tan, Y, García-Cao, M, Liu, F, Cheng, G, Hatlen, M, Xu, H, Shah, R, Chastain, N, Liu, N, Huang, G, Zhou, Y, Sheng, M, Song, J, Yang, F-C, Benezra, R, Nimer, SD & Wang, L 2016, 'Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin', Blood, vol. 127, no. 19, pp. 2322-2326. https://doi.org/10.1182/blood-2015-11-677708
Man, Na ; Sun, Xiao Jian ; Tan, Yurong ; García-Cao, Marta ; Liu, Fan ; Cheng, Guoyan ; Hatlen, Megan ; Xu, Haiming ; Shah, Ronit ; Chastain, Nolan ; Liu, Na ; Huang, Gang ; Zhou, Yuan ; Sheng, Mengyao ; Song, Junhong ; Yang, Feng-Chun ; Benezra, Robert ; Nimer, Stephen D ; Wang, Lan. / Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin. In: Blood. 2016 ; Vol. 127, No. 19. pp. 2322-2326.
@article{8f3d3328ea7a4af18bfabee926e00429,
title = "Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin",
abstract = "Inhibitor of DNA binding 1 (Id1) functions as an E protein inhibitor, and overexpression of Id1 is seen in acute myeloid leukemia (AML) patients. To define the effects of Id1 on leukemogenesis, we expressed MLL-AF9 in fetal liver (FL) cells or bone marrow (BM) cells isolated from wild-type, Id1-/-, p21-/-, or Id1-/- p21-/- mice, and transplanted them into syngeneic recipient mice. We found that although mice receiving MLL-AF9 - transduced FL or BM cells develop AML, loss of Id1 significantly prolonged the median survival of mice receiving FL cells but accelerated leukemogenesis in recipients of BM cells. Deletion of Cdkn1a (p21), an Id1 target gene, can rescue the effect of Id1 loss in both models, suggesting that Cdkn1a is a critical target of Id1 in leukemogenesis. It has been suggested that the FL transplant model mimics human fetal-origin (infant) MLL fusion protein (FP)-driven leukemia, whereas the BM transplantation model resembles postnatal MLL leukemia; in fact, the analysis of clinical samples from patients with MLL-FP+ leukemia showed that Id1 expression is elevated in the former and reduced in the latter type of MLL-FP+ AML. Our findings suggest that Id1 could be a potential therapeutic target for infant MLL-AF9-driven leukemia.",
author = "Na Man and Sun, {Xiao Jian} and Yurong Tan and Marta Garc{\'i}a-Cao and Fan Liu and Guoyan Cheng and Megan Hatlen and Haiming Xu and Ronit Shah and Nolan Chastain and Na Liu and Gang Huang and Yuan Zhou and Mengyao Sheng and Junhong Song and Feng-Chun Yang and Robert Benezra and Nimer, {Stephen D} and Lan Wang",
year = "2016",
doi = "10.1182/blood-2015-11-677708",
language = "English (US)",
volume = "127",
pages = "2322--2326",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",

}

TY - JOUR

T1 - Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin

AU - Man, Na

AU - Sun, Xiao Jian

AU - Tan, Yurong

AU - García-Cao, Marta

AU - Liu, Fan

AU - Cheng, Guoyan

AU - Hatlen, Megan

AU - Xu, Haiming

AU - Shah, Ronit

AU - Chastain, Nolan

AU - Liu, Na

AU - Huang, Gang

AU - Zhou, Yuan

AU - Sheng, Mengyao

AU - Song, Junhong

AU - Yang, Feng-Chun

AU - Benezra, Robert

AU - Nimer, Stephen D

AU - Wang, Lan

PY - 2016

Y1 - 2016

N2 - Inhibitor of DNA binding 1 (Id1) functions as an E protein inhibitor, and overexpression of Id1 is seen in acute myeloid leukemia (AML) patients. To define the effects of Id1 on leukemogenesis, we expressed MLL-AF9 in fetal liver (FL) cells or bone marrow (BM) cells isolated from wild-type, Id1-/-, p21-/-, or Id1-/- p21-/- mice, and transplanted them into syngeneic recipient mice. We found that although mice receiving MLL-AF9 - transduced FL or BM cells develop AML, loss of Id1 significantly prolonged the median survival of mice receiving FL cells but accelerated leukemogenesis in recipients of BM cells. Deletion of Cdkn1a (p21), an Id1 target gene, can rescue the effect of Id1 loss in both models, suggesting that Cdkn1a is a critical target of Id1 in leukemogenesis. It has been suggested that the FL transplant model mimics human fetal-origin (infant) MLL fusion protein (FP)-driven leukemia, whereas the BM transplantation model resembles postnatal MLL leukemia; in fact, the analysis of clinical samples from patients with MLL-FP+ leukemia showed that Id1 expression is elevated in the former and reduced in the latter type of MLL-FP+ AML. Our findings suggest that Id1 could be a potential therapeutic target for infant MLL-AF9-driven leukemia.

AB - Inhibitor of DNA binding 1 (Id1) functions as an E protein inhibitor, and overexpression of Id1 is seen in acute myeloid leukemia (AML) patients. To define the effects of Id1 on leukemogenesis, we expressed MLL-AF9 in fetal liver (FL) cells or bone marrow (BM) cells isolated from wild-type, Id1-/-, p21-/-, or Id1-/- p21-/- mice, and transplanted them into syngeneic recipient mice. We found that although mice receiving MLL-AF9 - transduced FL or BM cells develop AML, loss of Id1 significantly prolonged the median survival of mice receiving FL cells but accelerated leukemogenesis in recipients of BM cells. Deletion of Cdkn1a (p21), an Id1 target gene, can rescue the effect of Id1 loss in both models, suggesting that Cdkn1a is a critical target of Id1 in leukemogenesis. It has been suggested that the FL transplant model mimics human fetal-origin (infant) MLL fusion protein (FP)-driven leukemia, whereas the BM transplantation model resembles postnatal MLL leukemia; in fact, the analysis of clinical samples from patients with MLL-FP+ leukemia showed that Id1 expression is elevated in the former and reduced in the latter type of MLL-FP+ AML. Our findings suggest that Id1 could be a potential therapeutic target for infant MLL-AF9-driven leukemia.

UR - http://www.scopus.com/inward/record.url?scp=84993661823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993661823&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-11-677708

DO - 10.1182/blood-2015-11-677708

M3 - Article

C2 - 26944543

AN - SCOPUS:84993661823

VL - 127

SP - 2322

EP - 2326

JO - Blood

JF - Blood

SN - 0006-4971

IS - 19

ER -